Moderna (MRNA) and Pharma Stocks Surge Amid Hantavirus Concerns
Published on · Source: cnbc.com
AI Summary
Summarized by AI from the source belowFollowing the World Health Organization's announcement of a hantavirus outbreak on May 2, several pharmaceutical stocks, including Moderna (MRNA), experienced significant gains. Moderna's shares increased by 7% in premarket trading as the company is conducting preclinical research on the hantavirus. Inovio Pharmaceuticals reported a 13% rise, while Emergent Biosolutions and Novavax gained 4% and 3%, respectively. Analysts from Evercore ISI suggested that any revenue potential for Moderna related to hantavirus is unlikely, viewing stock movements as sentiment-driven rather than fundamentally driven.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Moderna Inc. (MRNA)
Moderna is a biotech pioneering mRNA vaccines and therapeutics.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier MRNA news
MRNA stock page and all news →Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
